Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | SPTLC2 | O15270 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046817 | 1.00 | KMT2A (0.52) | KMT2ATAS1R3TAS1R1CCR2PTGS2 | |
| SCHEMBL8206232 | 0.91 | CA1 (0.50) | KMT2ATAS1R3TAS1R1CCR2PDE4A | |
| SCHEMBL8206229 | 0.91 | CA1 (0.50) | KMT2ATAS1R3TAS1R1CCR2PDE4A | |
| SCHEMBL6167797 | 0.89 | SPTLC2 (0.45) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL6167795 | 0.89 | SPTLC2 (0.45) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL7204083 | 0.87 | TAS1R3 (0.51) | KMT2ATAS1R3TAS1R1PDE4APDE4B | |
| SCHEMBL5737318 | 0.87 | TAS1R3 (0.51) | KMT2ATAS1R3TAS1R1PDE4APDE4B | |
| SCHEMBL5053376 | 0.87 | TAS1R3 (0.51) | KMT2ATAS1R3TAS1R1PDE4APDE4B | |
| SCHEMBL7402512 | 0.86 | MCHR1 (0.52) | KMT2ATAS1R3TAS1R1PDE4APDE4B | |
| SCHEMBL7402511 | 0.86 | MCHR1 (0.52) | KMT2ATAS1R3TAS1R1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250325-B1 | PHENANTHRIDINE-N-OXIDES | NYCOMED GMBH (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-6630483-B2 | Phenanthridine-N-oxides | ALTANA PHARMA AG (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20030105123-A1 | For therapy of respiratory system disorders | ALTANA PHARMA AG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1250325-A1 | PHENANTHRIDINE-N-OXIDES | ALTANA Pharma AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001051470-A1 | PHENANTHRIDINE-N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105123-A1 | For therapy of respiratory system disorders | CHRM3, CYP11B1, CYP11B2 | KMT2A 3871/4885TAS1R3 1467/4885TAS1R1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.